Form 4 for ALLR Allarity Therapeutics, Inc.
Accepted 2026-05-14 11:48:38 ET · period of report 2026-01-28 · accession 0001213900-26-056373 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 11:48 | 2026-01-28 | ALLR | Jensen Thomas | CEO | A - Grant | $0.00 | +200.0K | 596.7K | +50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-28 | A | A | 200,000 | $0.00 | 596,734 | D | — | — | (F1) The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date. |